Vaccine Biomarker Services for Development
Advanced vaccine biomarker and bioanalytical services supporting the development of vaccines to combat infectious diseases.
Expert Vaccine Development and Immunogenicity Testing
Synexa Life Sciences offers a comprehensive array of solutions designed to assess the efficacy and immunogenicity of vaccine candidates. Our vaccine services are meticulously designed to investigate both cellular and humoral immune responses, providing a holistic view of vaccine efficacy.
Utilising advanced techniques such as flow cytometry, MHC multimer analysis, and cutting-edge immunoassays, we enable customers to delve deeply into the immune responses elicited by vaccines. Through rigorous evaluations, we empower customers with the critical data needed to make informed decisions, facilitating the development of vaccines that are both safe and effective.
Vaccine Biomarker and Bioanalytical Services
Serum Proteomics
Gain a systemic view of immune activation and signaling pathways with high-throughput proteomic analysis.
- Olink proteomics platform to quantify expression levels of up to 92 immune-related proteins in serum, enabling biomarker discovery and mechanistic insights
Cellular Immunogenicity
Our cellular assays provide deep insights into T cell-mediated immunity, which is critical to long-term protection and vaccine efficacy.
- Measurement of vaccine-specific T cell responses using ELISpot or FluoroSpot
- flow cytometry for comprehensive profiling of antigen-specific T cells through intracellular cytokine staining (ICS), activation-induced markers (AIM), and proliferation assays
- Multimer staining for high-resolution detection of antigen-specific T cells
Humoral Immunogenicity
We provide advanced solutions to evaluate vaccine-induced antibody responses, ensuring robust assessment of humoral immunity.
- Quantification of vaccine-specific immunoglobulins using ligand-binding ELISA and MSD platforms
- B Cell ELISpot for precise measurement of antigen-specific B cell activity
- Cell-based neutralisation assays (e.g., reporter and pseudovirus systems) for accurate detection of neutralising antibodies
Supporting Global Vaccine Initiatives
Synexa is proud to be a member of the Coalition for Epidemic Preparedness Innovations’ (CEPI) Clinical Laboratory Network and Global Central Laboratory Network Advisory Council (GCAC), supporting CEPI’s global initiative to accelerate vaccine development and improve worldwide epidemic preparedness.
Our extensive clinical network supports CEPI by enabling access to convalescent samples for in vitro assessment of vaccine antigen immunogenicity.
More on Vaccines
Behind The Wave: The Importance of Post-Market Surveillance and its Pertinence to the COVID-19 Pandemic
Improving the World’s First Malaria Vaccine
Challenges and Opportunities: Development of the HIV vaccine
From Pottiphar to Potts: Skeletal TB from Ancient Egypt to the Present Day
The mpox outbreak: Variants, transmission and the boost for vaccine manufacturers
Building a bioanalytical workflow for a vaccine study: The key assays and considerations
Building a bioanalytical workflow for a vaccine study: The key assays and considerations
The mpox outbreak: Variants, transmission and the boost for vaccine manufacturers
From Pottiphar to Potts: Skeletal TB from Ancient Egypt to the Present Day
Improving the quality of human health
Contact us
Discuss biomarker and bioanalytical solutions to accelerate your therapeutic pipeline
